Endava Ltd. DAVA 深 滬
等待開盤 08-06 09:30:00 美东时间
12.16
-0.020
-0.16%
華盛通- 最 高12.2867
- 今 開12.19
- 成交量 23.70万股
- 最 低 11.90
- 昨 收 12.18
- 總市值 6.98亿
- 52周最高 34.94
- 市盈率 靜 33.14
- 換手率 0.41%
- 52周最低 11.80
- 委 比 33.33%
- 總股本 5741.72万
- 歷史最高 172.41
- 量 比 0.65
- 振 幅 3.17%
- 歷史最低 11.80
- 每 手 1
- 風險率 18.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Forecasting The Future: 9 Analyst Projections For Endava
9 analysts have expressed a variety of opinions on Endava (NYSE:DAVA) over the ...
07-18 03:00
Deutsche Bank Reinstates Hold on Endava, Announces $14 Price Target
Deutsche Bank analyst Nate Svensson reinstates Endava (NYSE:DAVA) with a Hold and announces $14 price target.
07-17 23:48
Endava Announces Formation Of Its Global Advisory Board
The Global Advisory Board brings together renowned business leaders to advise, guide and champion Endava's leadership position within the technology industryEndava (NYSE:DAVA), a leading business transformation group
06-24 19:43
美股大行评级 | 潜在涨幅434.95%！VNRX获Jones Trading首予"买入"评级，目标价3美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Metsera(MTSR)"买入"评级，目标价从56美元升至62美元</p> <p>• 摩根大通：维持Avidity Biosciences(RNA)"超配"评级，目标价从57美元升至59美元</
06-11 09:43
Forecasting The Future: 5 Analyst Projections For Endava
Providing a diverse range of perspectives from bullish to bearish, 5 analysts h...
06-10 21:00
Needham Maintains Buy on Endava, Raises Price Target to $20
Needham analyst Mayank Tandon maintains Endava (NYSE:DAVA) with a Buy and raises the price target from $18 to $20.
06-10 18:22
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
Susquehanna Maintains Positive on Endava, Lowers Price Target to $42
Susquehanna analyst James Friedman maintains Endava (NYSE:DAVA) with a Positive and lowers the price target from $50 to $42.
05-20 22:26
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
05-20 09:28
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
